COPPELL, Texas--(BUSINESS WIRE)--Mannatech, Incorporated (NASDAQ: MTEX), the founder of the M5MSM (Mission 5 MillionSM) social entrepreneurial movement, the pioneer of nutritional glycobiology and the global innovator of naturally sourced supplements based on Real Food Technology® solutions, announced that it will release a limited supply of Manapol powder, which will be exclusively available in the U.S. on August 19.
Manapol is a pure, premium, 100 percent aloe vera gel extract, designed to support cell-to-cell communication.* Mannatech’s offering has a guaranteed molecular weight of more than one million Daltons1, testing the highest of any other aloe gel extract available in the world today. Rich in acetylated mannans found in the inner leaf gel of the aloe, this product supports the body’s immune system and may also provide gastrointestinal benefits.*
For more than 20 years, Manapol has been a key ingredient in many Mannatech products such as Advanced Ambrotose® and Ambrotose complex, and is finally being released as a standalone product after years of requests.
Manapol powder will be launching exclusively for Associate attendees of the Los Angeles Super Regional meeting, August 14-15, 2015. The official launch for all other U.S. Mannatech Associates and the general public will be on Wednesday, August 19.
For more information on the launch of Manapol, visit the website. To register for the Los Angeles Super Regional meeting, please visit the event site.
Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing childhood nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico, Namibia, Spain and Hong Kong. For more information, visit Mannatech.com.
Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
1 The Chemical Abstract Society (CAS) has defined acemannan as requiring a molecular weight of one million Daltons or more.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.